Area of research
Neurology · Cancer Research
Research interest
Research interests include Neuroblastoma Research and Treatments, Cancer, Hypoxia, and Metabolism, Cancer therapeutics and mechanisms, and Adrenal and Paraganglionic Tumors.
International neuroblastoma risk group consortium: a model of networking for rare cancers.
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.
Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Contemporary Ototoxicity Among Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL1531
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group
A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.
International neuroblastoma risk group consortium: a model of networking for rare cancers
Long‐Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology Group
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Adaptive Clinical Neuroblastoma Risk Groups—Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification
Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report